Survodutide (Boehringer Ingelheim/Zealand code BI 456906) is a once-weekly dual agonist of the glucagon and GLP-1 receptors. The GLP-1 side does the familiar incretin work; the glucagon side is the differentiator, adding an energy-expenditure and liver-fat angle that has made survodutide especially interesting for liver disease, not just weight.
Research Background
Survodutide was discovered by Boehringer Ingelheim and is co-developed with Zealand Pharma. It's a glucagon-based analog with a fatty-acid chain that supports weekly dosing, and its glucagon-to-GLP-1 activity ratio was tuned to capture the hepatic and energy-expenditure benefits of glucagon without pushing blood sugar up. After positive phase 2 results in both obesity and MASH in 2024, it moved into a phase 3 program (SYNCHRONIZE), including a dedicated cardiovascular outcomes trial.
How It Works
The GLP-1 receptor arm suppresses appetite through hypothalamic satiety pathways, slows gastric emptying, and supports glucose-dependent insulin secretion. The glucagon receptor arm adds two things GLP-1 alone doesn't: increased energy expenditure (thermogenesis) and a direct action on the liver that promotes fat oxidation and lipolysis. That hepatic effect is why survodutide has drawn attention for metabolic dysfunction-associated steatohepatitis (MASH), where reducing liver fat and fibrosis is the goal.
What the Research Shows
- Obesity, phase 2 (le Roux et al., The Lancet Diabetes & Endocrinology, 2024): across a dose range over 46 weeks, survodutide produced dose-dependent, statistically significant weight loss, with a tolerability profile in line with the GLP-1 class.
- MASH, phase 2 (Sanyal et al., NEJM, 2024): MASH improvement without worsening of fibrosis occurred in roughly 47–62% of survodutide participants (dose-dependent) versus about 14% on placebo — the primary endpoint. Fibrosis improved by at least one stage in about a third of treated participants, and a majority saw liver-fat reductions of 30% or more.
- Preclinical basis (Zimmermann et al., Molecular Metabolism, 2022): in animal models, the anti-obesity effect came from both increased energy expenditure (the glucagon arm) and reduced food intake (the GLP-1 arm), confirming the dual-mechanism rationale.
Storage & Handling
Survodutide is supplied in lyophilized (freeze-dried) form. Store it at -20°C or below, protected from light and moisture. Reconstitute immediately before use with a sterile solvent, and avoid repeated freeze-thaw cycles.
Frequently Asked Questions
How is survodutide different from tirzepatide?
Both are dual agonists, but they target different second receptors. Tirzepatide pairs GLP-1 with GIP; survodutide pairs GLP-1 with glucagon, which adds energy expenditure and a direct liver-fat effect.
Why is survodutide studied for liver disease?
The glucagon-receptor arm acts on the liver to drive fat oxidation, so it's a natural candidate for MASH — and its phase 2 liver data (Sanyal 2024) were strong enough to earn regulatory Breakthrough Therapy attention.
What purity does Dynamite Research Peptides provide?
Our survodutide is 99%+ purity with a Certificate of Analysis for every batch.
All products are for research use only — not for human or animal consumption.